Pētniecības projekta nosaukums: Nr. F-JP2-21 “Primāro šūnu zarnas uz čipa modelis perorāli lietojamo medikamentu efekta novēršanai uz zarnu cilmes šūnām”

Pētniecības projekts tiek īstenots SIA “Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centrs” projekta Nr. 5.1.1.2.i.0/2/24/A/CFLA/005 ietvaros  

‍

This project aims to develop a personalised NSCLC patient lung cancer on chip (LCoC) and lung on chip (LoC) as a model system where to test the efficacy of drug-loaded patient-derived MSC produced EVs compared to the drug by itself.

This project aims at developing a radically new technology for non-invasive detection and monitoring of prostate cancer (PC) based on label-free quantification of PC-derived extracellular vesicles (EVs) and analysis of their RNA content. This technology will combine a multi-stage microfluidic system with optical resonators and novel reagents – nanobodies allowing to capture, quantify and analyse the RNA cargo of specific PC-derived EV subpopulations in the blood or urine.

The project aims to improve the cultivation of patient-derived cell cultures in OOC (Organ-on-Chip) equipment by applying real-time machine learning algorithms to microfluidics and using light-field microscopy, transepithelial electrical resistance, and O2 sensor data.

This project aims to overcome technical challenges when working with organ on chip models in biological safety level 3 (BSL3) environment and microgravity by developing enclosed test system capable of cultivating cells and be compatible with BLS3 workflow and microgravity systems.